Related Experiment Video
Updated: Jul 12, 2025

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
Published on: December 13, 2018
LncRNA CALML3-AS1 modulated by m6A modification induces BTNL9 methylation to drive non-small-cell lung cancer
Heng Zhang1,2,3, Shao-Qiang Wang4,5, Jie-Bo Zhu6
1Department of Thoracic Surgery, Xiangya Hospital, Central South University, Changsha, 410008, Hunan Province, P. R. China. 404346@csu.edu.cn.
Abstract:
Non-small cell lung cancer (NSCLC) is a common and lethal malignancy. The carcinogenic roles of lncRNA CALML3 antisense RNA 1 (CALML3-AS1) have been documented. However, the function and potential mechanisms of CALML3-AS1 in the progression of NSCLC need to be further explored. The molecule expression was assessed by qRT-PCR and Western blot. The subcellular localization of CALML3-AS1 was observed by fluorescence in situ hybridization (FISH). The malignant behaviors of NSCLC cells were evaluated by CCK-8, colony formation, EdU, wound healing and transwell assays. In vivo xenograft tumor and liver metastatic models were established. The molecular mechanisms were investigated by RIP, RNA pull-down and ChIP assays. The methylation level was detected by MSP. Herein, we found that CALML3-AS1 was upregulated, while butyrophilin-like 9 (BTNL9) was downregulated in NSCLC. Functionally, CALML3-AS1 depletion repressed NSCLC cell malignant phenotypes, in vivo tumor growth, and liver metastasis. Mechanistically, AlkB homolog 5 (ALKBH5) enhanced CALML3-AS1 stability via N6-methyladenosine (m6A) demethylation, whereas m6A reader YTH domain-containing 2 (YTHDC2) destabilized CALML3-AS1. Moreover, CALML3-AS1 inhibited BTNL9 transcription and expression through the recruitment of Zeste homolog 2 (EZH2). Rescue experiments demonstrated that BTNL9 downregulation counteracted sh-CALML3-AS1-mediated antitumor effects on NSCLC. Taken together, CALML3-AS1 modulated by ALKBH5 and YTHDC2 in an m6A modification dependent manner drives NSCLC progression via epigenetically repressing BTNL9.
Insights
Long non-coding RNA CALML3-AS1 promotes non-small cell lung cancer (NSCLC) progression. It enhances tumor growth and metastasis by epigenetically silencing BTNL9, modulated by m6A modification.
Area of Science:
- Molecular Oncology
- Epigenetics
- Non-small Cell Lung Cancer (NSCLC) Research
Background:
- Non-small cell lung cancer (NSCLC) is a leading cause of cancer-related mortality.
- The long non-coding RNA CALML3 antisense RNA 1 (CALML3-AS1) has been implicated in carcinogenesis, but its precise role and mechanisms in NSCLC require further elucidation.
Purpose of the Study:
- To investigate the functional role of CALML3-AS1 in NSCLC progression.
- To elucidate the underlying molecular mechanisms by which CALML3-AS1 influences NSCLC pathogenesis, including its interaction with epigenetic regulators and target genes.
Main Methods:
- Quantitative real-time PCR (qRT-PCR) and Western blot for gene expression analysis.
- Fluorescence in situ hybridization (FISH) for subcellular localization.
- Cellular assays (CCK-8, colony formation, EdU, wound healing, Transwell) and in vivo models (xenograft, liver metastasis) to assess malignant behaviors.
- RNA immunoprecipitation (RIP), RNA pull-down, and chromatin immunoprecipitation (ChIP) assays to investigate molecular interactions.
- Methylation-specific PCR (MSP) to detect methylation levels.
Main Results:
- CALML3-AS1 was significantly upregulated, while butyrophilin-like 9 (BTNL9) was downregulated in NSCLC tissues and cells.
- Depletion of CALML3-AS1 suppressed NSCLC cell proliferation, migration, invasion, tumor growth, and liver metastasis.
- CALML3-AS1 stability is regulated by N6-methyladenosine (m6A) modification, with AlkB homolog 5 (ALKBH5) enhancing its stability and YTH domain-containing 2 (YTHDC2) destabilizing it.
- CALML3-AS1 epigenetically repressed BTNL9 expression by recruiting Zeste homolog 2 (EZH2).
- Restoration of BTNL9 expression partially rescued the antitumor effects of CALML3-AS1 knockdown.
Conclusions:
- CALML3-AS1 acts as a crucial oncogenic lncRNA in NSCLC, promoting malignant phenotypes and metastasis.
- The ALKBH5/m6A/YTHDC2 axis modulates CALML3-AS1 stability, influencing its oncogenic function.
- CALML3-AS1 drives NSCLC progression by epigenetically inhibiting BTNL9, highlighting a potential therapeutic target.
More Related Videos
Related Concept Videos
lncRNA - Long Non-coding RNAs
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
MicroRNAs
Abnormal Proliferation
Non-LTR Retrotransposons
Master Transcription Regulators

